Citations

Showing 10 of 108104 citations.

Examiner accuracy in cognitive testing in multisite brain-tumor clinical trials: an analysis from the Alliance for Clinical Trials in Oncology
Cerhan, Jane H. , Anderson, S. Keith , Butts, Alissa M. , Porter, Alyx B. , Jaeckle, Kurt A. , Brown, Paul D. , Jaeckle, Kurt, Galanis, Evanthia

Mayo Clinic

Neuro-Oncology Practice | November 24, 2018 | Volume: 6 | Issue: 4 | Pages: 283-288

10.1093/nop/npy048 | PMID 31386061 Get It

Abstract Background Cognitive function is an important outcome in brain-tumor clinical trials. Cognitive examiners are often needed across multiple sites, many of whom have no prior testing experience. To ensure quality, we looked at examiner errors in administering a commonly used cognitive test battery, determined whether the errors were correctable upon central review, and considered whether the same errors would be detected using onsite electronic data entry. Methods We looked at 500 cognitive exams administered for brain-tumor trials led by the Alliance for Clinical Trials in Oncology (Alliance). Of 2277 tests examined, 32 noncorrectable errors were detected with routine central review (1.4% of tests administered), and thus removed from the database of the respective trial. The invalidation rate for each test was 0.8% for each part of the Hopkins Verbal Learning Test-Revised, 0.8% for Controlled Oral Word Association, 1.8% for Trail Making Test-A and 2.6% for Trail Making Test-B. It was estimated that, with onsite data entry and no central review, 4.9% of the tests entered would have uncorrected errors and 1.3% of entered tests would be frankly invalid but not removed. Conclusions Cognitive test results are useful and robust outcome measures for brain-tumor clinical trials. Error rates are extremely low, and almost all are correctable with central review of scoring, which is easy to accomplish. We caution that many errors could be missed if onsite electronic entry is utilized instead of central review, and it would be important to mitigate the risk of invalid scores being entered. ClinicalTrials.gov identifiers NCT01781468 (Alliance A221101), NCT01372774 (NCCTG N107C), NCT00731731 (NCCTG N0874), and NCT00887146 (NCCTG N0577).
Feedback on LH in Testosterone-Clamped Men Depends on the Mode of Testosterone Administration and Body Composition
Roelfsema, Ferdinand , Yang, Rebecca , Liu, Peter Y. , Veldhuis, Johannes D. , Yang, Rebecca J, Takahashi, Paul Y. , Veldhuis, Johannes D

Mayo Clinic

Journal of the Endocrine Society | November 23, 2018 | Volume: 3 | Issue: 1 | Pages: 235-249

10.1210/js.2018-00317 | PMID 30623162 Get It

Sensor Technology Embedded in Stents: A Potential New Approach to Continuous Monitoring for in Stent Stenosis, Thrombosis, and Beyond
Abi-Aad, Karl R., Welz, Matthew E., Hess, Ryan A. , Bendok, Bernard R. , Hess, Ryan

Mayo Clinic

Neurosurgery | November 23, 2018 | Volume: 84 | Issue: 3 | Pages: E132-E133

10.1093/neuros/nyy616 | PMID 30690481 Get It

Diagnosis of Attenuated Mucopolysaccharidosis VI: Clinical, Biochemical, and Genetic Pitfalls
Conboy, Erin , Jones, Amie, Barnett, Sarah , Klee, Eric W. , Lanpher, Brendan C. , Barnett, Sarah S, Vairo, Filippo Pinto e , Souza, Carolina Fischinger Moura de

Mayo Clinic

Pediatrics | November 23, 2018 | Volume: 142 | Issue: 6 | Pages: No page available

10.1542/peds.2018-0658 | PMID 30470723 Get It

Mucopolysaccharidosis type VI (MPS VI) is a clinically heterogeneous lysosomal disease, which can be divided into 2 main categories on the basis of age of onset and severity of symptoms. The diagnosis of the attenuated form is often delayed given subtle facial features rather than the typical coarse facial features of the classic form. Here, we discuss the difficulties in establishing the diagnosis of MPS VI on the basis of the report of 4 individuals. The most common signs and symptoms in our series were bone abnormalities and hip pain as initial manifestations and cardiac changes detected after follow-up studies. On the basis of our cohort and others worldwide, awareness of attenuated forms of MPS VI should be increased particularly among general practitioners, pediatricians, rheumatologists, orthopedists, ophthalmologists, and cardiologists. Moreover, these health care providers should be aware of the technical aspects involved in the molecular and biochemical diagnosis process so that they are aware how diagnostic errors may occur.
Psychological and Genetic Predictors of Pain Tolerance
Patanwala, Asad E. , Norwood, Charles , Steiner, Heidi E. , Morrison, Daniel, Li, May, Walsh, Keith, Martinez, M. Elena, Baker, Sarah E. , Snyder, Eric M., Karnes, Jason H. , Baker, Sarah E

Mayo Clinic

Clinical and Translational Science | November 23, 2018 | Volume: 12 | Issue: 2 | Pages: 189-195

10.1111/cts.12605 | PMID 30468309 Get It

Previous studies have shown associations between genetic polymorphisms and pain tolerance, but psychological evaluations are seldom measured. The objective of this study was to determine the independent effects of demographic, psychological, and genetic predictors of cold noxious pain tolerance. Healthy subjects (n = 89) completed the Pain Catastrophizing Scale (PCS) and Fear of Pain Questionnaire (FPQ‐III), underwent genotyping for candidate single nucleotide polymorphisms (SNPs), and completed a cold‐pressor test in a 1–2°C water bath for a maximum of 3 minutes. The primary outcome measure was pain tolerance, defined as the maximum duration of time subjects left their nondominant hand in the cold‐water bath. Cox proportional hazards regression indicated that female sex, Asian race, and increasing PCS and FPQ‐III scores were associated with lower pain tolerance. No candidate SNP was significantly associated with pain tolerance. Future genetic studies should include demographic and psychological variables as confounders in experimental pain models.
MRI Outperforms [18F]AV‐1451 PET as a Longitudinal Biomarker in Progressive Supranuclear Palsy
Whitwell, Jennifer L. , Tosakulwong, Nirubol , Botha, Hugo , Senjem, Matthew L. , Spychalla, Anthony J., Ahlskog, J. Eric , Petersen, Ronald C. , Jack, Clifford R. , Lowe, Val J. , Josephs, Keith A. , Jack, Clifford R , Senjem, Matthew L , Botha, Hugo , Schwarz, Christopher G. , Knopman, David S.

Mayo Clinic

Movement Disorders | November 23, 2018 | Volume: 34 | Issue: 1 | Pages: 105-113

10.1002/mds.27546 | PMID 30468693 Get It

AbstractBackgroundElevated uptake of the [18F]AV‐1451 tau‐PET ligand has been observed cross‐sectionally in subjects with progressive supranuclear palsy (PSP). However, it is unknown how the ligand performs longitudinally in PSP. We aimed to determine how regional measures of change on [18F]AV‐1451 PET perform as longitudinal biomarkers of PSP compared with the more established biomarker of rate of midbrain atrophy.MethodsSixteen subjects with PSP underwent 2 serial [18F]AV‐1451 tau‐PET scans and 3‐Tesla MRI over 12 months and were age‐ and sex‐matched to 39 healthy controls with longitudinal [18F]AV‐1451 PET. Median [18F]AV‐1451 uptake was calculated for each scan for regions of interest across the brain and divided by uptake in cerebellar crus to create standard uptake value ratios. Midbrain volume on MRI was also calculated for each scan. Sample sizes required to power placebo‐controlled treatment trials were calculated.ResultsRate of midbrain atrophy was significantly increased in PSP compared with controls. [18F]AV‐1451 regional change measures were significantly increased in PSP compared with controls in the pallidum, precentral cortex, dentate nucleus of the cerebellum, and midbrain. Change over time in the PSP Rating Scale correlated with change in midbrain volume but did not correlate with change in the [18F]AV‐1451 measures. Smallest sample‐size estimates were obtained with rate of midbrain atrophy, followed by the PSP Rating Scale, with both outperforming [18F]AV‐1451 measures.Conclusions[18F]AV‐1451 tau‐PET measures increase over time in subjects with PSP, but longitudinal [18F]AV‐1451 measures may not perform as well as rate of midbrain atrophy as biomarkers for PSP clinical trials. © 2018 International Parkinson and Movement Disorder Society
Characterization of Farnesyl Diphosphate Farnesyl Transferase 1 ( FDFT1 ) Expression In Cancer
Tüzmen, Şükrü , Watanabe, Aprill, Ekmekçi, Cumhur Gökhan , Carrigan, Patricia E., Shechter, Ishaiahu, Kallioniemi, Olli , Mousses, Spyro, Miller, Laurence J. , Hostetter, Galen H.

Mayo Clinic

Personalized Medicine | November 23, 2018 | Volume: 16 | Issue: 1 | Pages: 51-65

10.2217/pme-2016-0058 | PMID 30468409 Get It

A Comparison of Partial Volume Correction Techniques for Measuring Change in Serial Amyloid PET SUVR
Gunter, Jeffrey L. , Lowe, Val J. , Weigand, Stephen D. , Vemuri, Prashanthi , Senjem, Matthew L. , Petersen, Ronald C. , Jack, Clifford R. , Jack, Clifford R , Vemuri, Prashanthi , Senjem, Matthew L , Schwarz, Christopher G. , Knopman, David S.

Mayo Clinic

Journal of Alzheimer's Disease | November 23, 2018 | Volume: 67 | Issue: 1 | Pages: 181-195

10.3233/jad-180749 | PMID 30475770 Get It

Rapamycin improves healthspan but not inflammaging in nfκb1−/− mice
Correia‐Melo, Clara , Birch, Jodie , Fielder, Edward , Rahmatika, Dina , Taylor, Jennifer, Chapman, James , Lagnado, Anthony B. , Carroll, Bernadette , Miwa, Satomi , Richardson, Gavin D. , Jurk, Diana , Oakley, Fiona , Mann, Jelena , Mann, Derek A. , Passos, João F. , Lagnado, Anthony, Jurk, Diana , Passos, João F , Richardson, Gavin D , Taylor, Jennifer, Korolchuk, Viktor I.

Mayo Clinic

Aging Cell | November 23, 2018 | Volume: 18 | Issue: 1 | Pages: No page available

10.1111/acel.12882 | PMID 30468013 Get It

AbstractIncreased activation of the major pro‐inflammatory NF‐κB pathway leads to numerous age‐related diseases, including chronic liver disease (CLD). Rapamycin, an inhibitor of mTOR, extends lifespan and healthspan, potentially via suppression of inflammaging, a process which is partially dependent on NF‐κB signalling. However, it is unknown if rapamycin has beneficial effects in the context of compromised NF‐κB signalling, such as that which occurs in several age‐related chronic diseases. In this study, we investigated whether rapamycin could ameliorate age‐associated phenotypes in a mouse model of genetically enhanced NF‐κB activity (nfκb1−/−) characterized by low‐grade chronic inflammation, accelerated aging and CLD. We found that, despite showing no beneficial effects in lifespan and inflammaging, rapamycin reduced frailty and improved long‐term memory, neuromuscular coordination and tissue architecture. Importantly, markers of cellular senescence, a known driver of age‐related pathology, were alleviated in rapamycin‐fed animals. Our results indicate that, in conditions of genetically enhanced NF‐κB, rapamycin delays aging phenotypes and improves healthspan uncoupled from its role as a suppressor of inflammation.
Medialization laryngoplasty/arytenoid adduction: U.S. outcomes, discharge status, and utilization trends
Ekbom, Dale C. , Orbelo, Diana M. , Sangaralingham, Lindsey R. , Mwangi, Raphael , Houten, Holly K. Van , Balakrishnan, Karthik , Van Houten, Holly K, Orbelo, Diana , Balakrishnan, Karthik

Mayo Clinic

The Laryngoscope | November 23, 2018 | Volume: 129 | Issue: 4 | Pages: 952-960

10.1002/lary.27538 | PMID 30467860 Get It

Objectives/HypothesisTo evaluate trends, outcomes, and healthcare utilization following medialization laryngoplasty (ML) with or without arytenoid adduction (AA) over 10 years.Study DesignRetrospective observational study.MethodsUsing OptumLabs Data Warehouse, trends, outcomes, and healthcare utilization from 2006 to 2015 were examined with a focus on discharge type (same day or not). Predictors of postoperative emergency department (ED) use and hospitalization were determined by multivariable logistic regression.ResultsOverall rate of ML was 1.09 per 100 thousand enrollees per year. Of these, 7.8% ML were combined with an AA. Outpatient same‐day discharge represented 62.0% (1,142 of 1,843) of total patients, steadily increasing over the 10‐year period (P < 0.01). There was a 5.9% revision ML rate and 1.0% rate of tracheotomy within 1 day of ML. A total of 5.6% visited an ED, and 5.4% were admitted to a hospital following initial discharge within 30 days. Same‐day discharge was found to be a predictor of hospitalization within 30 days after ML (odds ratio [OR] 1.74, P = 0.0452), along with Elixhauser comorbidity index of 4 + (OR 5.74, P = 0.0001). Pulmonary embolism, pulmonary hypertension, and weight loss were top predictors of ED visit or hospitalization.ConclusionTo our knowledge, this is the first search evaluating national claims data for ML with or without AA. Overall rate of ML is low, and same‐day discharge has become more common over a 10‐year period, with an associated higher 30‐day hospital admission risk. Correct patient selection criteria for disposition status cannot be fully determined based on current data, but a high Elixhauser comorbidity index clearly carries increased risk for hospitalization after initial discharge.Level of Evidence4 Laryngoscope, 129:952–960, 2019